Innate and adaptive immunity in inflammatory bowel disease.
暂无分享,去创建一个
G. Corazza | A. Di Sabatino | P. Biancheri | Antonio Di Sabatino | Paolo Biancheri | Gino R Corazza | Alessandra Geremia | Philip Allan | A. Geremia | P. Allan
[1] R. Baldassano,et al. Intestinal Interleukin-13 in Pediatric Inflammatory Bowel Disease Patients , 2004, Inflammatory bowel diseases.
[2] S. Romagnani. Lymphokine production by human T cells in disease states. , 1994, Annual review of immunology.
[3] J. Ioannidis,et al. Differential Effects of NOD2 Variants on Crohn's Disease Risk and Phenotype in Diverse Populations: A Metaanalysis , 2004, The American Journal of Gastroenterology.
[4] P. Nos,et al. Nuevos conocimientos en genética y enfermedad inflamatoria intestinal. ¿alguna utilidad práctica? , 2011 .
[5] T. Hibi,et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease , 2008, Gut.
[6] M. Pop,et al. Metagenomic Analysis of the Human Distal Gut Microbiome , 2006, Science.
[7] Judy H. Cho,et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.
[8] J. D. Di Santo,et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3−NKp46+ cell subsets from Id2-dependent precursors , 2010, The Journal of experimental medicine.
[9] K. Takeuchi,et al. The increased mucosal mRNA expressions of complement C3 and interleukin‐17 in inflammatory bowel disease , 2010, Clinical and experimental immunology.
[10] T. Macdonald,et al. What's the next best cytokine target in IBD? , 2012, Inflammatory bowel diseases.
[11] Tariq Ahmad,et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 , 2011, Nature Genetics.
[12] M. Weichenthal,et al. Inducible and Constitutive &bgr;-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis , 2003, Inflammatory bowel diseases.
[13] D. Levy,et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways , 2007, Nature Immunology.
[14] T. Macdonald. Inside the microbial and immune labyrinth: Totally gutted , 2010, Nature Medicine.
[15] D. Philpott,et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry , 2010, Nature Immunology.
[16] V. Deretic,et al. Toll‐like receptors control autophagy , 2008, The EMBO journal.
[17] T. Macdonald,et al. IL‐23/IL‐17 axis in IBD , 2010, Inflammatory bowel diseases.
[18] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[19] H. Tilg,et al. XBP1 Links ER Stress to Intestinal Inflammation and Confers Genetic Risk for Human Inflammatory Bowel Disease , 2008, Cell.
[20] S. Barry,et al. Foxp3+ Regulatory T Cells, Th17 Effector Cells, and Cytokine Environment in Inflammatory Bowel Disease , 2009, Journal of Clinical Immunology.
[21] P. Mannon,et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. , 2004, The Journal of clinical investigation.
[22] M. Neurath,et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. , 1996, Journal of immunology.
[23] Steven J. Schrodi,et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. , 2007, American journal of human genetics.
[24] A. O’Garra,et al. Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.
[25] H. Spits,et al. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells , 2010, The Journal of experimental medicine.
[26] T. Macdonald,et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. , 2005, Gastroenterology.
[27] H. Reinecker,et al. NF-kappa B-inducing kinase is a common mediator of IL-17-, TNF-alpha-, and IL-1 beta-induced chemokine promoter activation in intestinal epithelial cells. , 1999, Journal of immunology.
[28] P. Lipsky,et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. , 2006, Blood.
[29] P. Rutgeerts,et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis , 2004, Gut.
[30] Simon C. Potter,et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants , 2007, Nature Genetics.
[31] Judy H. Cho,et al. Functional consequences of NOD2 (CARD15) mutations , 2006, Inflammatory bowel diseases.
[32] Judy H. Cho,et al. [Letters to Nature] , 1975, Nature.
[33] P. Lionetti,et al. Proteolytic degradation of intestinal mucosal extracellular matrix after lamina propria T cell activation. , 1996, Gut.
[34] R. D. Hatton,et al. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.
[35] J. Spencer,et al. Targeting Gut T Cell Ca2+ Release-Activated Ca2+ Channels Inhibits T Cell Cytokine Production and T-Box Transcription Factor T-Bet in Inflammatory Bowel Disease , 2009, The Journal of Immunology.
[36] F. Powrie,et al. Control of intestinal inflammation by regulatory T cells , 2001, Immunological reviews.
[37] Yusuke Nakamura,et al. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease , 2002, Journal of Human Genetics.
[38] T. Macdonald,et al. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. , 2001, The Journal of clinical investigation.
[39] W. Sandborn,et al. Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.
[40] T. Giese,et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. , 2005, Gastroenterology.
[41] D. Rampton,et al. DIFFERENTIAL REGULATION OF INTERLEUKIN-17 AND INTERFERON- PRODUCTION IN INFLAMMATORY BOWEL DISEASE , 2011 .
[42] M. Neurath,et al. Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. , 2009, Gastroenterology.
[43] T. Toyota,et al. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. , 1995, Journal of gastroenterology.
[44] M. Netea,et al. A Crohn's disease–associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1 , 2009, Nature Immunology.
[45] Thomas Korn,et al. IL-17 and Th17 Cells. , 2009, Annual review of immunology.
[46] K. Fukase,et al. Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. , 2007, Molecular immunology.
[47] K. Kaukinen,et al. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells , 2005, Laboratory Investigation.
[48] Kan Yang,et al. Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2 , 2002, Science.
[49] A. Lindén,et al. Interleukin-17 family members and inflammation. , 2004, Immunity.
[50] Judy H. Cho,et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene , 2006, Science.
[51] J. Meijerink,et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. , 2006, Gastroenterology.
[52] U. Broeckel,et al. Comparative Phenotypic and CARD15 Mutational Analysis Among African American, Hispanic, and White Children with Crohn's Disease , 2005, Inflammatory bowel diseases.
[53] J A Walker-Smith,et al. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. , 1993, Immunology.
[54] R. Blumberg,et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. , 2002, Immunity.
[55] S. Travis,et al. IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.
[56] M. Neurath,et al. Transforming growth factor β induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis , 2005, Gut.
[57] D. McKay,et al. Interleukins 4 and 13 Increase Intestinal Epithelial Permeability by a Phosphatidylinositol 3-Kinase Pathway , 2000, The Journal of Biological Chemistry.
[58] M Schwab,et al. NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression , 2004, Gut.
[59] Alastair Forbes,et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility , 2007, Nature Genetics.
[60] A. Hart,et al. IL‐6 promotes immune responses in human ulcerative colitis and induces a skin‐homing phenotype in the dendritic cells and Tcells they stimulate , 2012, European journal of immunology.
[61] Ying Wang,et al. Genomewide association study of leprosy. , 2009, The New England journal of medicine.
[62] A. Andoh,et al. Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.
[63] M. Gaub,et al. Diminution of Circulating CD4+CD25high T Cells in Naïve Crohn’s Disease , 2009, Digestive Diseases and Sciences.
[64] A. Rizzo,et al. Regulation of gut inflammation and th17 cell response by interleukin-21. , 2008, Gastroenterology.
[65] Nancy Xiaonan Yu,et al. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study , 2001, American Journal of Gastroenterology.
[66] C. Bernstein,et al. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. , 2005, Gastroenterology.
[67] B. Vainer,et al. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. , 2000, Cytokine.
[68] C. Tato,et al. Innate IL-17-producing cells: the sentinels of the immune system , 2010, Nature Reviews Immunology.
[69] A. T. Te Velde,et al. Altered Expression of Interferon‐&ggr; and Interleukin‐4 in Inflammatory Bowel Disease , 1998, Inflammatory bowel diseases.
[70] R. D. Hatton,et al. Developmental plasticity of Th17 and Treg cells. , 2009, Current opinion in immunology.
[71] Mourad Sahbatou,et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.
[72] F. Powrie,et al. Innate lymphoid cells drive IL-23 dependent innate intestinal pathology , 2010, Nature.
[73] A. Fusco,et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. , 1999, Journal of immunology.
[74] D. Jewell,et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation , 2010, Nature Medicine.
[75] P. Desreumaux,et al. Abnormalities in mucin gene expression in Crohn's disease , 1999 .
[76] A. Vanoli,et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease , 2011, Mucosal Immunology.
[77] M. Weichenthal,et al. Reduced Paneth cell α-defensins in ileal Crohn's disease , 2005 .
[78] T. Macdonald,et al. Interferon‐gamma‐expressing cells are a major source of interleukin‐21 in inflammatory bowel diseases , 2010, Inflammatory bowel diseases.
[79] Judy H. Cho,et al. A Genome Scan in 260 Inflammatory Bowel Disease-Affected Relative Pairs , 2004, Inflammatory bowel diseases.
[80] C. Tato,et al. Lymphoid tissue inducer–like cells are an innate source of IL-17 and IL-22 , 2009, The Journal of experimental medicine.
[81] Marc Vandemeulebroecke,et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.
[82] L. Cardon,et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. , 1999, American journal of human genetics.
[83] S. Vermeire,et al. NOD2/CARD15 disease associations other than Crohn's disease , 2007, Inflammatory bowel diseases.
[84] Thomas B. Clarke,et al. Intracellular sensors of extracellular bacteria , 2011, Immunological reviews.
[85] D. Jewell,et al. The IL-23/IL-17 pathway in inflammatory bowel disease , 2012, Expert review of gastroenterology & hepatology.
[86] G. Corazza,et al. Proteases and the gut barrier , 2012, Cell and Tissue Research.
[87] J. Söderholm,et al. Importance of disrupted intestinal barrier in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.
[88] E. Loftus. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.
[89] A. Kaser,et al. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. , 2011, Gastroenterology.
[90] G. Corazza,et al. New Pathogenic Paradigms in Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.
[91] K. Papadakis,et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. , 2007, Clinical immunology.
[92] M. Zeitz,et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.
[93] Alastair Forbes,et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease , 2008, Nature Genetics.
[94] Thomas Lengauer,et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1 , 2007, Nature Genetics.
[95] J. Lennerz,et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity , 2009, Nature.
[96] P. Donnelly,et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region , 2010 .
[97] M. Cook,et al. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. , 2012, Autoimmunity reviews.
[98] R. Coffman,et al. T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cells , 2005, The Journal of experimental medicine.
[99] C. Buskens,et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues , 2013, Nature Immunology.
[100] Tomohiro Watanabe,et al. NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.
[101] G. Morrone,et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. , 1997, Gastroenterology.
[102] L. Cosmi,et al. Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.
[103] F. Martinon,et al. The inflammasomes: guardians of the body. , 2009, Annual review of immunology.
[104] T. Karlsen,et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis , 2008, Nature Genetics.
[105] T. Wynn,et al. Colitis and intestinal inflammation in IL10-/- mice results from IL-13Rα2-mediated attenuation of IL-13 activity. , 2011, Gastroenterology.